Chemomab Therapeutics

Contributing Author

Recent Articles by Chemomab Therapeutics

Nov-20	Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update CMMB -10.00% GlobeNewswire
Nov-06	Chemomab Announces Multiple Presentations at AASLD The Liver Meeting 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis CMMB GlobeNewswire
Aug-21	Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference CMMB GlobeNewswire
Aug-14	Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update CMMB -6.34% GlobeNewswire
Jun-30	Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25 CMMB GlobeNewswire
Jun-11	Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis CMMB -7.48% GlobeNewswire
Jun-03	Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis CMMB GlobeNewswire
May-15	Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update CMMB +6.61% GlobeNewswire
May-05	Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025 CMMB -6.34% GlobeNewswire